Cu 2 O nanocrystal model catalysts

Rapid Assembly of Ultrafine Palladium Nanoparticle-Decorated HOF-101 Triggered by Guest Enzyme Encapsulation

Rapid enzyme immobilization is essential for enzyme catalysis and sensing applications, yet constructing effective immobilization systems is challenging due to the need to balance enzyme activity with the properties of the surrounding framework. Herein, taking glucose oxidase (GOx) as a model, a rapid and straightforward approach was presented for synthesizing palladium nanoparticles (PdNPs)-decorated GOx encapsulated in HOF-101 nanocomposite materials (designated as PdNPs/GOx@HOF-101) through an in situ photoreduction and enzyme-triggering HOF-101 encapsulation. The enzyme's surface residues trigger the nucleation of HOF-101 around it through the hydrogen-bonded bio interface, completing the self-assembly of HOF-101 in 0.5 h. Furthermore, the biocomposites loaded with ultrafine PdNPs show satisfactory photoelectrochemical (PEC) properties. As a proof-of-concept, a PEC biosensor was constructed by utilizing PdNPs/GOx@HOF-101 as a photoactive probe, which can quickly and sensitively detect glucose and simultaneously remain stable within the circumstance of 30-60 °C and pH 4-8. These attributes pave the way for diverse applications, including improved enzyme immobilization techniques, advanced biosensors, and more efficient biocatalytic processes.

Tailoring the Hydrophobic Interface of Core-Shell HKUST-1@Cu2O Nanocomposites for Efficiently Selective CO2 Electroreduction

The electrochemical reduction of carbon dioxide (CO2) to ethylene creates a carbon-neutral approach to converting carbon dioxide into intermittent renewable electricity. Exploring efficient electrocatalysts with potentially high ethylene selectivity is extremely desirable, but still challenging. In this report, a laboratory-designed catalyst HKUST-1@Cu2O/PTFE-1 is prepared, in which the high specific surface area of the composites with improved CO2 adsorption and the abundance of active sites contribute to the increased electrocatalytic activity. Furthermore, the hydrophobic interface constructed by the hydrophobic material polytetrafluoroethylene (PTFE) effectively inhibits the occurrence of hydrogen evolution reactions, providing a significant improvement in the efficiency of CO2 electroreduction. The distinctive structures result in the remarkable hydrocarbon fuels generation with high Faraday efficiency (FE) of 67.41%, particularly for ethylene with FE of 46.08% (-1.0 V vs RHE). The superior performance of the catalyst is verified by DFT calculation with lower Gibbs free energy of the intermediate interactions with improved proton migration and selectivity to emerge the polycarbon（C2+） product. In this work, a promising and effective strategy is presented to configure MOF-based materials with tailored hydrophobic interface, high adsorption selectivity and more exposed active sites for enhancing the efficiency of the electroreduction of CO2 to C2+ products with high added value.

Cu Facet-Dependent Elementary Surface Reaction Kinetics of CO2 Hydrogenation to Methanol Catalyzed by ZrO2/Cu Inverse Catalysts

ZrO2-Cu-based catalysts are active in catalyzing the hydrogenation of CO2 to methanol. Herein, we report Cu facet effects on the catalytic performance of ZrO2/Cu inverse catalysts in CO2 hydrogenation to methanol using various Cu nanocrystals with well-defined Cu morphologies and facets. The ZrO2-Cu interface is the active site, in which the ZrO2-Cu{100} and ZrO2-Cu{110} interfaces exhibit similar apparent activation energies of ∼42.6 kJ/mol, smaller than that of the ZrO2-Cu{111} interface (∼64.5 kJ/mol). Temporal in situ diffuse reflectance infrared Fourier transform spectroscopy characterization results identify the bridge formate hydrogenation as the rate-determining elementary surface reaction under typical reaction temperatures, whose activation energy is similar at the ZrO2-Cu{100} (∼36.3 kJ/mol) and ZrO2-Cu{110} (∼40.5 kJ/mol) interfaces and larger at the ZrO2-Cu{111} interface (∼54.5 kJ/mol). This fundamental understanding suggests Cu facet engineering as a promising strategy to improve the catalytic performance of ZrO2/Cu inverse catalysts for CO2 hydrogenation to methanol.

Aptamer-Engineered Cu2O Nanocubes as a Surface-Modulated Catalytic Optical Sensor for Lung Cancer Cell Detection

Herein, fine and homogeneous Cu₂O nanocubes are synthesized and sensitized with a hairpin-structured AS1411 aptamer for the establishment of a biosensor for lung cancer cell detection. The Apt-Cu₂O nanocubes feature a recognition function in identifying a cancer-associated surface nucleolin protein. The intrinsic reduction catalytic ability is also confirmed by the use of two benchmark substrates, methylene blue (MB) and 4-nitrophenol (4-NP). The aptamer grafting on Apt-Cu₂O nanocubes is able to greatly prevent nonspecific-protein binding and to show specificity toward the nucleolin protein. The specific binding resulting from nucleolin protein leads to less exposure of the active area of the Apt-Cu₂O nanocubes, so the catalytic ability of Apt-Cu₂O nanocubes is thus diminished. The modulated catalytic ability led to less generation of the reduced 4-AP product, and the change in absorption of 4-AP allows the quantification of the nucleolin protein with a detection limit of 0.47 nM. The as-developed biosensor is applied to the detection of nucleolin-overexpressed A549 lung cancer cells, presenting a sensitive detection limit down to 20 cells. This may be ascribed to the clustering of surface nucleolin protein in a lipid raft membrane of cancer cells, as evidenced by a notable binding of Apt-Cu₂O nanocubes on the cancer cell surface. Real human serum samples spiked with cancer cells were also investigated, and a recovery rate of 87 ± 2.4% for 20 extracted cells validates the surface-modulated Apt-Cu₂O nanocubes-based catalytic optical biosensor as a promising tool for the detection of circulating tumor cells. The establishment of the Apt-Cu₂O nanocubes may allow for further studies on their use as a potential theranostics tool for cancer therapy.